ArticleInternational journal of surgery (London, England)2026
Effect of bariatric surgery and pharmacological treatments on cardiovascular risk factors for adults with overweight and obesity: a systematic review and network meta-analysis.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Adjunctive use of glucagon-like peptide-1 receptor agonists after bariatric surgery: updated systematic review and meta-analysis of randomized controlled trials.Acta diabetologica · 2026Review
- Development of a predictive model for postoperative erectile function recovery in male patients with incomplete traumatic cervical spinal cord injury.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo comprehensively evaluate the relative efficacy and safety of lifestyle interventions, pharmacological therapies (orlistat, liraglutide, and semaglutide), and bariatric surgeries [Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and biliopancreatic diversion (BPD)] on body weight and cardiovascular risk factors in adults with overweight and obesity. We conducted a systematic review and network meta-analysis of randomized controlled trials (RCTs). MATERIALS AND
methodsComprehensive searches were performed in PubMed, MEDLINE, Embase, and the Cochrane Library through 1 February 2025. The analysis focused on interventions in adults with overweight or obesity, assessing outcomes including changes in body mass index (BMI), glycated hemoglobin (HbA1c), lipids, blood pressure, and adverse events.
resultsThis network meta-analysis included 26 RCTs. Bariatric surgery was the most effective modality for improving body weight and the majority of cardiovascular risk factors. Among surgeries, BPD demonstrated the greatest reductions in weight, BMI, and low-density lipoprotein cholesterol, but was also associated with the highest risk of serious adverse events (SAEs). RYGB and SG produced comparable weight loss, though RYGB showed unique advantages in improving high-density lipoprotein cholesterol and metabolic outcomes. Among pharmacological agents, semaglutide was the most efficacious, achieving weight loss, BMI reduction, and blood pressure control comparable to RYGB and SG. While liraglutide showed strong effects on glycemic control, semaglutide consistently outperformed both liraglutide and orlistat across most other outcomes and had a lower risk of discontinuation than liraglutide. Importantly, pharmacological agents, particularly semaglutide, had a significantly lower risk of SAEs than surgery.
conclusionBariatric surgery provides the most potent efficacy for weight loss and cardiometabolic improvement, with BPD being the most effective but also highest-risk procedure. Semaglutide emerges as a formidable therapeutic alternative, offering a degree of efficacy comparable to RYGB and SG in many key domains but with a superior safety profile. These findings underscore the need to shift from a "one-size-fits-all" approach to an evidence-based, individualized strategy that aligns each intervention's distinct efficacy and safety profile with specific patient goals and risk tolerance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.